Shots:
Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipeline
Jay also spoke about the company’s IO targets and other under development immunotherapies
In addition, the interview provided the corporate and financial updates of the Pyxis Oncology
Smriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…
